Listen to Your Heart
Season 1
by Listen to Your Heart
What’s new in lipid management for people with diabetes or metabolic syndrome? Our host, Dr. George Thanassoulis, takes a deeper look into this topic with Dr. Priya Manjoo, an Endocrinologist and Certified Specialist in both Hypertension and Obesity Medicine at the Victoria Cardiometabolic Collaborative Clinic, and a Clinical Assistant Professor in the Division of Endocrinology at the University of British Columbia’s Faculty of Medicine. This episode discusses how the recently updated Canadian Cardiovascular Society Guidelines have changed the clinical practice of lipid management in patients with diabetes or who suffer from metabolic syndrome. Our experts also dive into the topics of why this patient subgroup is particularly at higher risk for cardiovascular complications, and how timely intensification of lipid-lowering therapy, through statin optimization and use of agents such as PCSK9 inhibitors, can lead to better outcomes for such patients. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Thanassoulis: Direct financial relationship including receipt of honoraria: Sanofi. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, Novartis, Silence. Dr. Manjoo: Direct financial relationship including receipt of honoraria: Amgen, Novo Nordisk, Bosch health, HLS therapeutics. Membership on advisory boards or speaker’s bureau: Novo Nordisk, Bosch health. Lilly, Amgen bone health.
What’s new in lipid management for those having experienced a recent acute coronary event? Our host, Dr. George Thanassoulis, takes a deeper look into this topic with Dr. Shaun Goodman, a Cardiologist and Associate Head in the Division of Cardiology, Department of Medicine, at St. Michael’s Hospital, and a Professor and Heart & Stroke Foundation of Ontario (Polo) Chair at the University of Toronto’s Department of Medicine. He is Co-Director of the Canadian VIGOUR (Virtual Coordinating Centre for Global Collaborative Cardiovascular Research) Centre. This episode discusses how the recently updated Canadian Cardiovascular Society Guidelines have changed the overall clinical practice of lipid management. Our experts touch on why those having acute coronary syndrome within the last year are at higher risk for subsequent events, and the importance of collaborative multidisciplinary care. They also discuss clinical evidence from the ODYSSEY OUTCOMES and FOURIER trials, demonstrating how this patient subgroup may benefit from more aggressive lowering of LDL cholesterol with PCSK9 inhibitors. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Thanassoulis: Direct financial relationship including receipt of honoraria: Sanofi. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, Novartis, Silence. Dr. Goodman: Direct financial relationship including receipt of honoraria: Heart and Stroke Foundation of Ontario/University of Toronto (Polo) Chair, Canadian Heart Failure Society, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, New York University Clinical Coordinating Centre, PERFUSE Research Institute, TIMI Study Group (Brigham Health). Membership on advisory boards or speaker’s bureau: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Merck, Novartis, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi, Servier, Tolmar Pharmaceuticals, Valeo Pharma. Funded grants, research or clinical trials: Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi.